{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T10:01:23Z","timestamp":1790935283898,"version":"4.1.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100006364","name":"INCa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jtho.2026.104091","type":"journal-article","created":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:07:52Z","timestamp":1790932072000},"page":"104091","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["No Longer a Luxury? MRD Dynamics as the Final Arbitrator for Cure in Locally Advanced NSCLC"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9909-2299","authenticated-orcid":false,"given":"Nicolas","family":"Girard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2026.104091_bib1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-year survival outcomes from the PACIFIC trial: durvalumab after chemoradiotherapy in Stage III non-small-cell lung cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.104091_bib2","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.jtho.2022.10.003","article-title":"Treatment characteristics and real-world progression-free survival in patients with unresectable Stage III NSCLC who received durvalumab after chemoradiotherapy: findings from the PACIFIC-R study","volume":"18","author":"Girard","year":"2023","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.104091_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2026.103992","article-title":"ctDNA-Based MRD detection in stage III NSCLC treated with chemoradiotherapy and durvalumab","volume":"21","author":"Horndalsveen","year":"2026","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.104091_bib4","article-title":"Predictive effectiveness of circulating tumor DNA in recurrent early-stage non-small cell lung cancer: an updated meta-analysis","volume":"9","author":"Lu","year":"2025","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.jtho.2026.104091_bib5","article-title":"CheckMate 73L: Phase III study comparing nivolumab (N) + concurrent chemoradiotherapy (CCRT) followed by N \u00b1 ipilimumab (I) v CCRT followed by durvalumab (D) for previously untreated, locally advanced stage (stg) III NSCLC","volume":"24","author":"Peters","year":"2024","journal-title":"ESMO IO-Tech"},{"key":"10.1016\/j.jtho.2026.104091_bib6","doi-asserted-by":"crossref","first-page":"S1610","DOI":"10.1016\/j.annonc.2025.09.081","volume":"36","author":"Dziadziuszko","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.104091_bib7","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1080\/14796694.2024.2354160","article-title":"PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer","volume":"20","author":"Barlesi","year":"2024","journal-title":"Future Oncol"},{"key":"10.1016\/j.jtho.2026.104091_bib8","doi-asserted-by":"crossref","first-page":"e342","DOI":"10.1016\/j.cllc.2022.04.003","article-title":"Rationale and design of the Phase III KEYLYNK-012 study of pembrolizumab and concurrent chemoradiotherapy followed by pembrolizumab with or without olaparib for Stage III non-small-cell lung cancer","volume":"23","author":"Jabbour","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2026.104091_bib9","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO-24-02347","article-title":"De-escalation strategies with immune checkpoint blockers in non-small cell lung cancer: do we already have enough evidence?","volume":"43","author":"Remon","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.104091_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1004574","article-title":"Recurrence prediction using circulating tumor DNA in patients with early-stage non-small cell lung cancer after treatment with curative intent: a retrospective validation study","volume":"22","author":"Schuurbiers","year":"2025","journal-title":"PLoS Med"},{"key":"10.1016\/j.jtho.2026.104091_bib11","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1056\/NEJMoa2502929","article-title":"First-line camizestrant for emerging ESR1-mutated advanced breast cancer","volume":"393","author":"Bidard","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426005447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426005447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T09:40:40Z","timestamp":1790934040000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086426005447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":11,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S1556086426005447"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2026.104091","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"No Longer a Luxury? MRD Dynamics as the Final Arbitrator for Cure in Locally Advanced NSCLC","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2026.104091","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2026.103992","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104091"}}